The wave of anesthesia has re-ed What are the big players in china's anesthesia market?

Narcotic drugs are drugs that can cause temporary, reversible loss of consciousness and pain throughout the body or body.
generally divided into general anaesthetic, local anesthetic and anaesthetic aids.
Among them, narcotic drugs such as fentanyl, hydro morphine ketones, because of the irregular continuous use of dependence, addiction, belong to china's special management of drugs, related experimental research, production, operation, use, storage, transportation and other activities are strictly regulated, such as September 15, the General Office of the National Health and Health Commission issued the "National Health And Wellness Commission Office on strengthening the management of narcotic drugs and the first category of mental medicine management of medical institutions", to further strengthen the management of medical institutions.
, on the whole, the drug industry's professional and industry barriers are high, the domestic market competition pattern is relatively stable.
Affected by the outbreak of new crown pneumonia in the first half of the year, the number of patient visits and operations in medical institutions decreased, which caused a certain impact on the narcotic drug market, but with the outbreak prevention and control from emergency state to normal, market application gradually recovered.
in the context of innovation has become the main theme of the development of the pharmaceutical industry, since 2020, the major related enterprises as always, positive layout and made encouraging progress.
01 research and development results on the market in January, Enhua Pharmaceuticals 3 specifications of ethyl acetate ether injection was registered approval.
Ethyl acrylic hydrochloride injection is a selective anticholinent that can be used for pre-anesthesia to inhibit the secretion of salivary glands and gas glands, as well as for emergency treatment of organophosphate toxic (pesticide) poisoning and maintenance of attopicity after late poisoning or after aging of cholinesterase (ChE).
current manufacturers also include Aohong Pharmaceuticals, Watson Pharmaceuticals and Tiantaishan Pharmaceuticals.
new drug research and development monitoring database (CPM) in March, Yichang Peoplefu's hydrochloric acid afenthantini injection was approved for the market, this is the first time afentani products approved for the domestic market.
as an anesthetic analgesic, mainly used for general anaesthetic induction and maintenance, especially day/short surgery, medium- and long-term surgery, etc.
addition to Yichang People's Blessing, Enhua Pharmaceuticals' hydrochloric acid afentanine injection has also been declared for production and CDE acceptance.
new drug research and development monitoring database (CPM) in July, the first class of new drugs injected with human-fu medicine with benzoic sulphate remathram was approved for market.
injection of benzoic acid remazolun was jointly developed by Yichang Renfu in cooperation with PAION, Germany, for colonoscopy sedation.
The drug's clinical excellence challenges a new generation of sedative propofol, and has broad prospects for clinical application in the fields of painless sedative sedation, general anesthesia, ICU sedation and bureau sedation.
it is worth mentioning that Hengrui Pharmaceuticals Class 1 new drug injection toluene sulfonate remathorum was approved for the market in December last year, and has been approved gastroscopy and colonoscopy to check for sedative 2 adaptive disorders.
, Hengrui Pharmaceuticals was approved for the first time in China in accordance with the three declared ammonium glilong bromide injections.
Grome ammonium bromide injection is an anticholinel-energy drug that has an anticholinel-like effect and can be used directly intramyal or intravenously for gastrointestinal diseases or anesthesia, and is expected to compete for part of the atomin market after its launch.
addition to Hengrui Pharmaceuticals, there are currently 7 clinical approvals for the drug, including Coastal Pharmaceuticals, Jiabo Pharmaceuticals and Yuandong Bio.
addition, Huahai Pharmaceuticals' short application (ANDA) for a new drug for Glon bromine injections was approved by the FDA in 2018, but has not yet been approved for the domestic market.
New Drug Research and Development Monitoring Database (CPM)02 Innovative research and development advanced in August when Trevena Inc.'s class 1 new drug TRV-130 injection application was approved by the FDA to treat moderate to severe acute pain in adult patients who need intravenous opioids.
Pharmaceuticals owns the exclusive license rights for TRV-130 to develop and commercialize in China.
, the product is still in the domestic clinical research stage, the approval in the United States will help speed up its clinical trial process in the country.
In August, Hesco's clinical application for a class 1 new drug HSK3486 emulsion was accepted by the National Drug Administration, which marked the product's application for a new adaptation "all-hemp maintenance" Phase III clinical trial, if successful in the relevant clinical trials will hopefully further broaden its indications and enhance market competitiveness.
HSK3486 as the company developed a new intravenous narcotic drug with independent intellectual property rights, intended for surgical full hemp induction, endoscopy sedation / anesthesia, ICU sedation and other adaptive disorders.
the drug has been conducted for digestive endoscopy, hemp induction, fiber mirror adaptation of three Phase III. clinical trials.
September, PCCW's registration status for propofol-medium/long-chain fat emulsions under category 4 was changed to "in-approval" and is expected to be approved and evaluated for the first time.
propofol/long-chain fat emulsion is a fast and short-acting intravenous anesthetic widely used in peri-surgical anesthesia induction, anaesthetic maintenance, and sedation in ICU wards.
the current domestic approved enterprises Garbo Pharmaceuticals and Guorui Pharmaceuticals have submitted a consistent evaluation review of supplementary applications, the drug approved import enterprises for Germany's Fessenyuskabi and Belang.
.